https://www.selleckchem.com/products/gsk3326595-epz015938.html newborn leptin and lipid levels, and efforts on improving maternal sleep during late pregnancy should be advocated for children's health. The aim of our study was to evaluate the association between insulin resistance and the response to IFN-alpha and ribavirin in pediatric patients with chronic hepatitis C. Twenty-six patients with chronic hepatitis C (mean age 12.5 ± 1.96 years, M/F3.33) were included in the study. Fasting glucose, insulin, and C-peptide levels, together with HOMA-IR, HOMA-B, and QUICKI values, were assessed. The association between those parameters and treatment response was determined. Five (19.2%) of the 26 patients analyzed (2 [21.4%] with treatment response and 3 [16.6%] with no treatment response) had insulin resistance (p=1.00). There were no significant differences between the patients with and without treatment response with respect to fasting glucose, insulin, and C-peptide levels or HOMA-IR, HOMA-B, and QUICKI values (p>0.05). No significant association was establihed between insulin resistance and response to IFN-alpha and ribavirin, in children with chronic hepatitis C. No significant association was establihed between insulin resistance and response to IFN-alpha and ribavirin, in children with chronic hepatitis C. Antiangiogenic treatments play an important role in the therapeutic strategy for metastatic renal cell carcinoma. Apatinib is an oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor-2. We aimed to assess the efficacy and safety of apatinib therapy in metastatic renal cell carcinoma patients. Between January 2018 and November 2018, we enrolled 53 metastatic renal cell carcinoma patients. Apatinib was administered at an initial dose of 500 mg once daily. The disease control rate, objective response rate, progression-free survival, and adverse events were reviewed and evaluated. Among the 53 patients, 14 achieved partial response